OS Therapies (OSTX) announced it has entered into an asset purchase agreement to acquire the listeria monocytogenes-based immuno-oncology programs and related intellectual property assets from Ayala ...
NEW YORK--(BUSINESS WIRE)-- OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results